{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-001473","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.233985+00:00","generated_at":"2026-05-30T22:13:55.139528+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexaria Bioscience appoints Michael Shankman as CFO, effective Oct 1, 2024","bullets":["Michael Shankman, CPA, replaces resigned CFO Nelson Cabatuan; CEO Richard Christopher had been interim principal financial officer.","Shankman previously served as outsourced CFO via NowCFO from June 2023 to February 2024.","Compensation: base salary with inflation-adjusted annual increases; performance bonuses up to 35-50% of base salary.","Granted incentive stock option for 50,000 shares at $3.17 exercise price, vesting in three tranches through August 31, 2026.","Severance: if terminated without cause after 6 months, two months' base salary plus one additional month per year of service."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-001473","json":"https://secwatch.observer/filing/0001640334-24-001473.json","markdown":"https://secwatch.observer/filing/0001640334-24-001473.md","text":"https://secwatch.observer/filing/0001640334-24-001473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:13:55.139528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"074b8353a8","claim":"Nelson Cabatuan resigned as Chief Financial Officer at Lexaria Bioscience Corp..","evidence_excerpt":"replacing Lexaria’s former CFO, Nelson Cabatuan who resigned effective July 15, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"60eaa0536c","claim":"Richard Christopher changed role as principal financial officer (interim) at Lexaria Bioscience Corp..","evidence_excerpt":"Richard Christopher, the Company’s Chief Executive Officer who assumed the responsibilities as the Company’s principal financial officer on an interim basis, relinquished those responsibilities to Mr. Shankman.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"relinquished responsibilities"},{"label":"Role","value":"principal financial officer (interim)"}],"fact_type":"executive_change"},{"claim_id":"ac77ddb58c","claim":"Michael Shankman was appointed as Chief Financial Officer at Lexaria Bioscience Corp..","evidence_excerpt":"Effective October 1, 2024, Michael Shankman, age 64, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001473/0001640334-24-001473-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}